Table 1 Clinical phenotypes of 1215 1000IBD participants
From: The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients; data release 1
No. of participants | 1215 |
Age (Median ± IQR) | 41 ± 25 |
Sex | |
Male (%) | 510 (41.97) |
Female (%) | 705 (58.03) |
Diagnosis | |
Crohn’s Disease (%) | 615 (50.62) |
Ulcerative Colitis (%) | 495 (40.74) |
IBDU (%) | 61 (5.02) |
Other (microscopic colitis, IBDI, reconsidering IBD diagnosis) (%) | 44 (3.62) |
Montreal Classification | |
A: Age of Onset | |
A1 (%) | 159 (13.09) |
A2 (%) | 710 (58.44) |
A3 (%) | 253 (20.82) |
L: Disease Location (CD only) | |
L1 (%) | 224 (36.42) |
L2 (%) | 120 (19.51) |
L3 (%) | 255 (41.46) |
L4 (%) | 65 (10.57) |
B: Disease Behaviour (CD only) | |
B1 (%) | 301 (48.94) |
B2 (%) | 208 (33.82) |
B3 (%) | 102 (16.58) |
Perianal | 189 (30.73) |
E: Disease Extent (UC only) | |
E1 (%) | 57 (10.25) |
E2 (%) | 162 (29.13) |
E3 (%) | 299 (53.78) |
S: Disease Severity (UC only) | |
S1 (%) | 29 (5.22) |
S2 (%) | 139 (25.00) |
S3 (%) | 191 (34.35) |
S4 (%) | 119 (21.40) |
Age at Diagnosis in years (Median ± IQR) | 27 ± 19 |
Disease Duration at Recruitment in years (Median ± IQR) | 8 ± 12 |
Medication Exposure | |
Steroids % | 90.07 |
Steroids CD % | 91.99 |
Steroids UC % | 88.28 |
Steroids IBDU % | 88.33 |
Immunosuppressors % | 68.32 |
Immunosuppressors CD % | 79.08 |
Immunosuppressors UC % | 56.97 |
Immunosuppressors IBDU % | 56.67 |
Biologicals % | 37.30 |
Biologicals CD % | 55.07 |
Biologicals UC % | 17.37 |
Biologicals IBDU % | 25.00 |
Mesalazines % | 44.34 |
Mesalazines CD % | 18.06 |
Mesalazines UC % | 70.99 |
Mesalazines IBDU % | 83.33 |
Average Disease Activitya | |
HBI (Average ± Standard Deviation) | 2.99 ± 3.18 |
SSCAI (Average ± Standard Deviation) | 1.61 ± 1.97 |